Sanofi | SNY - Cash And Equivalent


Sanofi reported EUR7.66B in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
AbbVie USD 5.23B 400M Dec/2025
Amgen USD 9.13B 316M Dec/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Canopy Growth CAD 298.06M 171.86M Sep/2025
Corcept Therapeutics USD 120.49M 4.64M Dec/2025
Drreddys Laboratories INR 18.66B 9.65B Dec/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
Galapagos EUR 64.46M 43.61M Sep/2025
Genmab DKK 1.3B 323M Jun/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
Glaxosmithkline GBP 3.3B 303M Sep/2025
J&J USD 19.71B 1.48B Dec/2025
Merck USD 18.17B 10.16B Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Pacira USD 147.59M 152.89M Sep/2025
Perrigo USD 432.1M 22.1M Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Phibro Animal Health USD 55.49M 17.28M Dec/2025
Prestige Brands USD 62.37M 56.73M Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Supernus Pharmaceuticals USD 151.37M 6.66M Sep/2025
UCB EUR 1.57B 1.14B Dec/2024
Zoetis USD 2.08B 649M Sep/2025